

About the Cancer Innovation Coalition (CIC)

The Cancer Innovation Coalition (CIC) is a collaboration of cancer stakeholder organizations and 21st century thinkers working to put cancer innovation on the policy agenda. Spearheaded by the National Patient Advocate Foundation (NPAF), the CIC is the driving force behind a new social activation movement called Project Innovation intended to deliver more promising new cancer treatments to patients quickly and save lives.

The impetus for Project Innovation was the release in June 2014 of a new NPAF white paper, *Securing the Future of Innovation in Cancer Treatment*, which identified institutional, regulatory and funding hurdles that are driving up the costs and delaying the development of new cancer therapies – factors that ultimately limit patient access to much needed treatment. To develop this policy blueprint, NPAF invited a range of health policy stakeholder organizations to participate in the CIC and provide their intellectual contributions to the preparation of the paper.

CIC members that contributed to the development of *Securing the Future of Innovation in Cancer Treatment* include: the Association of Community Cancer Centers, Bristol-Myers Squibb, the Cancer Support Community, Celgene Corporation, the Colon Cancer Alliance, the Council for Affordable Health Care, Friends of Cancer Research, Genentech, GlaxoSmithKline, Eli Lilly & Company, the National Patient Advocate Foundation, Novartis, the Oncology Nursing Society, Pfizer Inc. and the US Oncology Network.

Now that the white paper has been issued, the Cancer Innovation Coalition has expanded into a broad-based network of healthcare stakeholders that support Project Innovation by educating their constituencies on the issues presented in *Securing the Future of Innovation in Cancer Treatment*, enlisting local cancer patients and advocates to voice their concerns to policymakers, and advancing specific policy solutions in three key areas:

- Reducing regulatory and logistical obstacles that delay drug development
- Encouraging a new wave of experimentation through research funding
- Enhancing the delivery of innovation through improved communication and coordination between providers and patients.

Members of the Cancer Innovation Coalition are: Amgen, American Association for Cancer Research, American Cancer Society Cancer Action Network, Association of Community Cancer Centers, Bladder Cancer Advocacy Network, Bristol-Myers Squibb, Cancer Support Community, Celgene Corporation, Colon Cancer Alliance, Community Oncology Alliance, Council for Affordable Health Care, CureSearch, Cutaneous Lymphoma Foundation, Fight Colorectal Cancer, Friends of Cancer Research, Eli Lilly & Company, Genentech, GlaxoSmithKline, National Patient Advocate Foundation, Novartis, Oncology Nursing Society, Personalized Medicine Coalition, Pfizer, Inc., Prevent Cancer Foundation, and US Oncology Network.

Primary funding for this initiative comes from NPAF with additional support through research grants from Celgene Corporation, Eli Lilly, Novartis and Pfizer. More information about Project Innovation is available at www.projectinnovation.org, @projectinno on Twitter and <https://facebook.com/ProjectInno> on Facebook or by contacting the National Patient



Advocate Foundation at www.npaf.org or (202) 347-8009. Project Chair: Nancy Davenport-Ennis, NPAF's Founder and Chairman of the Board of Directors.

#####